Medicus Pharma Enters Co-Development & License Deal with Pfizer

What Happened
Medicus Pharma Ltd., through its subsidiary Medicus Pharma Inc., announced on Sept. 2, 2026 that it entered into a Co-Development and License Agreement with Pfizer Inc. under which Medicus receives an exclusive, sublicensable, royalty-bearing worldwide license to develop, manufacture and commercialize PF-08046031 (CD228V), an early clinical-stage antibody‑drug conjugate targeting CD228 (melanotransferrin). The agreement is structured as a co-development arrangement: Pfizer will remain involved, provide oversight rights (review/comment on plans and budgets), and holds an option to fund development from and after the first pivotal trial, while Medicus retains sole authority and responsibility for development, manufacturing, regulatory approval and commercialization.

Key Details

• Effective date: September 2, 2026. Agreement filed as Exhibit 10.1 (certain portions redacted).
• Payments: Medicus paid Pfizer a $12.0 million non‑refundable upfront on the effective date and owes an additional $15.0 million on the first anniversary. Pfizer paid Medicus a $2.0 million one-time Development Funding Payment to be used solely for CD228V development.
• Potential future payments: Aggregate potential development, regulatory and sales milestones exceed $1.0 billion across indications; Pfizer is also eligible for low double‑digit tiered royalties on annual net sales (product-by-product, country-by-country).
• Intellectual property & control: Pfizer retains ownership and will prosecute/maintain licensed patent rights; Medicus has exclusive development/commercial control and bears development and commercialization costs. Pfizer has no approval or veto rights but can opt to fund pivotal-stage development under a separate negotiated agreement.

Why It Matters
For investors, the deal validates Medicus’s CD228V program with a major pharma partner and provides immediate funding ($2.0M to Medicus; $12.0M received by Pfizer from Medicus) and defined future payment obligations (additional $15.0M due). The structure preserves Medicus’s operational control over development and commercialization but commits the company to fund programs and to pay milestones/royalties if products succeed. The agreement also gives Pfizer continued economic exposure via milestone and royalty streams and an option to fund later-stage development, which could affect future capital needs or partner dynamics.